Biologicals
1Divisão de Reumatologia, Clínica de Oncologia (CLION), Salvador, BA, Brazil
2Zabludowicz Center for Autoimmune Diseases, Tel Hashomer, Israel; Sheba Medical Center, Tel-Aviv University, Tel Aviv, Israel
3Rheumatology Unit, Department of Medicine, Faculty of Medical Sciences, State University of Campinas, Campinas, SP, Brazil
Biologicals
Description
New therapeutical biological agents for rheumatic disease have changed the prognosis of these diseases. In fact, for those patients who do not have good response to conventional therapy, biologicals are an alternative scheme to control disease activity. Knowledge and understanding of these novel therapeutical agents have led to the development of animal models, biological registries in diverse countries, and therapeutical strategies culminating in a better care to patients. We are interested in original and review articles that explore diverse aspects of biologicals in rheumatic diseases in humans and also in animal models. Potential topics include, but are not limited to:
- Biologicals in rheumatoid arthritis
- Biologicals in spondyloarthritis
- Biologicals in juvenile idiopathic arthritis
- Side effects during the use of biologicals in rheumatic conditions
- Infections and biologicals
- Vaccination and biologicals
- Peculiar and uncommon effects, such as in bone, heart, lungs, endocrine system, of the biological therapy in rheumatic disorders
Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ijr/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: